Two previous trials failed to demonstrate the effectiveness of statins for preventing adverse cardiovascular events in patients on dialysis (JW Cardiol Aug 19 2005 and Mar 30 2009). In SHARP, a randomized trial, investigators compared simvastatin plus ezetimibe with placebo. Of the 9270 patients (age, ≥40; mean age, 62; 63% men) with chronic kidney disease and no histories of acute myocardial infarction (AMI) or coronary revascularization, about one third were on dialysis. The study was funded by the drug combination's manufacturer, who participated in the study design.
Patients had creatinine levels of at least 1.7 mg/dL in men or 1.5 mg/dL in women. Nonadherent participants were excluded after a 6-week, single-blind, run-in placebo course.…
Reviewing Authors
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association